Anti-GD2 chimeric antigen receptor T cell therapy - Bellicum Pharmaceuticals

Drug Profile

Anti-GD2 chimeric antigen receptor T cell therapy - Bellicum Pharmaceuticals

Alternative Names: Anti-GD2 CAR transduced T cells - Bellicum Pharmaceuticals; Anti-GD2 CIDeCAR T cell therapy - Bellicum Pharmaceuticals; Anti-GD2 third party CAR T cell therapy - Bellicum Pharmaceuticals; GD2-CAR.OX40.28.z.ICD9

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Developer National Cancer Institute (USA)
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 31 Jan 2017 National Cancer Institute completes a phase I trial in Solid tumours (Second-line therapy or greater, Recurrent, Metastatic disease, In children, In adolescents, In adults) in USA (IV) (NCT02107963)
  • 01 Nov 2016 Bellicum and Ospedale Pediatrico Bambino Gesù collaborate on the development of CAR T-cell therapies and TCR cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top